Schizophrenia Clinical Trials in Riverside
View 130 new treatments for Schizophrenia in Riverside, CA, and nearby areas, such as Corona, Fontana, Jurupa Valley, Moreno Valley, Ontario, Rancho Cucamonga, Rialto, San Bernardino and Victorville. Every day, Power helps hundreds of schiz patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
RL-007 for Cognitive Impairment in Schizophrenia
Recognify Life Sciences Clinic, Orange + 5 more
This trial is testing a new drug, RL-007, to see if it can help people with schizophrenia think and remember better. The study will compare different doses of the drug and check for any side effects. Participants will take the drug for several weeks and complete memory and thinking tests before and after the treatment.Show More
Verified
Recruiting
Phase 2
Est. 3 - 6 Weeks
Gary Walker, PhD
Study Director
KarXT for Schizophrenia
Karuna Clinic, Anaheim + 8 more
This trial tests KarXT, a combination of two drugs, for people who haven't improved with their current treatment. KarXT aims to balance brain functions and reduce side effects. The study will look at improvements in health and daily life. KarXT has shown positive results in earlier tests.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
Ronald Marcus, MD
Study Director
Lumateperone for Schizophrenia and Bipolar Disorder
Intra-Cellular Therapies Clinic, Long Beach + 3 more
This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia or bipolar disorder.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Long-term Safety of Iclepertin for Schizophrenia
Boehringer Ingelheim Clinic, Santa Ana + 10 more
This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schizophrenia can tolerate a medicine called Iclepertin in the long term. Participants take Iclepertin as tablets once a day for 1 year. In addition, all participants take their normal medication for schizophrenia. Participants are in the study for a little more than 1 year. During this time, they visit the study site about 13 times and get about 9 phone calls from the study team. The doctors collect information on any health problems of the participants. Doctors also regularly check the participants' symptoms of schizophrenia.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team
Brilaroxazine for Schizophrenia
Reviva Clinic, Riverside + 2 more
This trial tests Brilaroxazine, a daily pill, in patients with severe mental health issues. It aims to improve mood and reduce symptoms. The study lasts for more than a year.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Medical Director
Study Director
SEP-363856 for Schizophrenia
Sunovion Clinic, Garden Grove + 3 more
This trial is testing a new schizophrenia medication called SEP-363856 in people who have already started using it. The goal is to see if it is safe and effective over several months. The medication works by affecting brain chemicals to help reduce symptoms of schizophrenia.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 6 - 12 Weeks
CNS Medical Director
Study Chair
KarXT for Schizophrenia
Karuna Clinic, Riverside + 3 more
The purpose of this study is to assess the safety and efficacy of slowly increasing dose and food effect of KarXT in adult participants with schizophrenia.
Recruiting
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Bristol-Myers Squibb
Study Director
KarXT for Schizophrenia
Karuna Clinic, Pico Rivera + 15 more
This trial tests the safety and tolerability of KarXT, a combination of two drugs, in schizophrenia patients who haven't responded well to their current treatments. KarXT aims to improve symptoms and manage side effects better than existing medications. KarXT (xanomeline plus trospium) is an emerging treatment for schizophrenia, showing promise in managing total, positive, and negative symptoms.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Bristol-Myers Squibb
Study Director
Iclepertin for Schizophrenia
Boehringer Ingelheim Clinic, Garden Grove + 4 more
This trial tests if a medicine called Iclepertin can help improve memory and learning in adults with schizophrenia. Participants take Iclepertin daily while continuing their usual medication. Doctors regularly check their mental abilities and health throughout the study. Iclepertin is being studied for its potential to improve cognitive functions in schizophrenia.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Dexmedetomidine for Agitation in Schizophrenia and Bipolar Disorder
BioXcel Clinic, Orange + 11 more
In this study, an investigational medication named BXCL501 is being tested for the treatment of episodes of agitation associated with bipolar I and bipolar II disorder, schizophrenia, schizoaffective and schizophreniform disorder. This study compares the study drug to a placebo.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
Robert Risinger, MD
Study Chair
Page 1 of 3
Frequently Asked Questions
Explore related conditions